 Rationale: Acute graft host disease GvHD remains a barrier to successful hematopoietic stem cell transplantation HCT used for the treatment of cancers in some patients. GvHD can result from a lack of compatibility between the donor and recipient. Research suggests another primary cause of GvHD comes from cytokines, or a substance produced by cells of the immune system that affect the immune response in both positive and negative ways. Infliximab is an antibody that directly targets the cytokine associated with GvHD. This study is building upon previous research to assess infliximabs ability to prevent GvHD after HCT. 